Protocol Ledger

NCT07777861 · Phase II · RECRUITING

A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy

Interventional Phase II clinical trial protocol NCT07777861 sponsored by Qingdao WanMing BioCell Pharmaceutics Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-18 Enrollment: 90 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07777861
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07777861
Protocol FieldVerified Registry Value
NCT IdentifierNCT07777861
Consolidated Lead SponsorQingdao WanMing BioCell Pharmaceutics Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment90 participants (ESTIMATED)
Registered Start Date2026-03-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI